Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8

详细信息    查看全文

• 作者：Takaaki Konuma¹ ; ^{tkonuma@ims.u-tokyo.ac.jp} ; Yasushi Miyazaki² ; Naoyuki Uchida³ ; Kazuteru Ohashi⁴ ; Tadakazu Kondo⁵ ; Hirohisa Nakamae⁶ ; Satoshi Takahashi⁷ ; Takehiko Mori⁸ ; Yukiyasu Ozawa⁹ ; Chiaki Kato¹⁰ ; Koji Iwato¹¹ ; Takahiro Fukuda¹² ; Tatsuo Ichinohe¹³ ; Yoshiko Atsuta¹⁴ ; ¹⁵ ; Ken Ishiyama¹⁶ ; for the Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation
• 关键词：Trisomy 8 ; Myelodysplastic syndrome ; Allogeneic hematopoietic stem cell transplantation ; Cytogenetics ; Additional abnormality
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：23
• 期：1
• 页码：75-80
• 全文大小：345 K
• 卷排序：23

文摘

The outcome and prognostic factors of allogeneic HSCT in adult patients with MDS harboring +8 were retrospectively analyzed. Age > 50 years, 2 or more additional cytogenetic abnormalities, and a high risk at the time of HSCT according to the FAB/WHO classification were significantly associated with a higher overall mortality. No significant impact on the outcome was observed in cases with 1 cytogenetic abnormality in addition to +8. Although more than half of the patients had advanced MDS at the time of HSCT, allogeneic HSCT offered a curative option for adult patients with MDS harboring +8.